Jin-Ji Yang

Yi-long Wu, Jin-Ji Yang, S. Chuai, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non-Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705).

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2022, Clinical lung cancer.

Genotyping of cerebrospinal fluid associated with osimertinib response and resistance for leptomeningeal metastases in EGFR-mutated non-small cell lung cancer.

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel.

Ying Cheng, Yi-long Wu, B. Han, 2018, Translational lung cancer research.

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

Jin-Ji Yang, K. Yin, Chongrui Xu, 2022, BMC Medicine.

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.

T. Yamanaka, M. Ahn, Yi-long Wu, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma

Yu Chen, Ji Chen, Jin-Ji Yang, 2022, Frontiers in Immunology.

Supraclavicular lymph node incisional biopsies have no influence on the prognosis of advanced non-small cell lung cancer patients: a retrospective study

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2017, World Journal of Surgical Oncology.

BRAIN study: it is hard to draw a conclusion - Authors' reply.

Jin-Ji Yang, Hong-Hong Yan, Yi-Long Wu, 2017, The Lancet. Respiratory medicine.

Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2021, European journal of cancer.

Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients

Yi-long Wu, Jin-Ji Yang, Y. Shao, 2020, Biomarker Research.

Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2020, Journal of thoracic disease.

A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival.

Yi-long Wu, Jin-Ji Yang, Chao Zhang, 2022, Lung cancer.

Complete remission and fatal interstitial pneumonitis related to nab‐paclitaxel in refractory small cell lung cancer: A case report and review of the literature

Jin-Ji Yang, Yilong Wu, Xuchao Zhang, 2012, Thoracic Cancer.

Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort Multicenter Interventional Study of Osimertinib with or Without Savolitinib in De Novo MET Aberrant, EGFR-Mutant Patients with Advanced Non-Small-Cell Lung Cancer: The FLOWERS Trial.

Jin-Ji Yang, Anna Li, Hua-jun Chen, 2022, Clinical lung cancer.

Distribution and prognosis of uncommon metastases from non-small cell lung cancer

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2016, BMC Cancer.

LBA2_PRGEFITINIB/CHEMOTHERAPY VS CHEMOTHERAPY IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION-POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC) AFTER PROGRESSION ON FIRST-LINE GEFITINIB: THE PHASE III, RANDOMISED IMPRESS STUDY

M. Ahn, T. Mok, Jin-Ji Yang, 2014 .

A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2019, Lung cancer.

Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes

Jin-Ji Yang, Chongrui Xu, Xuchao Zhang, 2022, Journal of Cancer Research and Clinical Oncology.

Association of Cerebrospinal Fluid Tumor DNA Genotyping With Survival Among Patients With Lung Adenocarcinoma and Central Nervous System Metastases

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2020, JAMA network open.

The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early-Invasive Lung Adenocarcinoma.

Yi-long Wu, Jin-Ji Yang, Chao Zhang, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2021, Cancer cell.

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Jian Su, Qing Zhou, Hai-Yan Tu, 2016, Clinical Cancer Research.

Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2018, Cancer Immunology, Immunotherapy.

Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2016, Oncotarget.

Mutational landscape and characteristics of ERBB2 in non‐small cell lung cancer

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2020, Thoracic cancer.

Toward innovative combinational immunotherapy: A systems biology perspective.

Yi-long Wu, Jin-Ji Yang, J. Hou, 2018, Cancer treatment reviews.

Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies

Yi-long Wu, Jin-Ji Yang, Chao Zhang, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Yi-long Wu, Jin-Ji Yang, S. Chuai, 2017, Clinical Cancer Research.

Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2021, Nature Communications.

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2010, Molecular Cancer.

Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC

Jin-Ji Yang, K. Yin, Xuchao Zhang, 2023, Cancers.

Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?

T. Mok, Jin-Ji Yang, Tony Mok, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study

Jin-Ji Yang, Chongrui Xu, Xuchao Zhang, 2023, Cell reports. Medicine.

Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma component.

T. Mok, Yi-long Wu, Jin-Ji Yang, 2010, Clinical lung cancer.

9132 POSTER Efficacy Outcomes in First-line Treatment of Advanced NSCLC With Gefitinib (G) vs Carboplatin/paclitaxel (C/P) by Epidermal Growth Factor Receptor (EGFR) Gene-copy Number Score and by Most Common EGFR Mutation Subtypes – Exploratory Data From IPASS

T. Mok, Yi-long Wu, S. Thongprasert, 2011 .

Plasma extracellular vesicle microRNAs for pulmonary ground-glass nodules

Jing Qin, Yi-long Wu, Jin-Ji Yang, 2019, Journal of extracellular vesicles.

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2011, European journal of cancer.

Impact of smoking status and pathologic type on epidermal growth factor receptor mutations in lung cancer.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2011, Chinese medical journal.

Prediction of unfavourable response to checkpoint blockade in lung cancer patients through an integrated tumour-immune expression score

Yi-long Wu, Jin-Ji Yang, K. Yin, 2021, Translational oncology.

Genomic Signatures Define Three Subtypes of EGFR-Mutant Stage II-III NSCLC With Distinct Adjuvant Therapy Outcomes

W. Mao, Ying Cheng, Yi-long Wu, 2021 .

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study.

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2015, Journal of Hematology & Oncology.

Establishment of a Novel Method for Screening Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Mutations in Lung Cancer

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2017, Chinese medical journal.

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2017, Lung cancer.

Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2020, Frontiers in Oncology.

Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC.

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2016, Clinical lung cancer.

MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2021, Experimental Hematology & Oncology.

Effects of epidermal growth factor receptor‐tyrosine kinase inhibitors alone on EGFR‐mutant non‐small cell lung cancer with brain metastasis

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2016, Thoracic cancer.

KRAS Mutation in Patients with Lung Cancer: A Predictor for Poor Prognosis but Not for EGFR-TKIs or Chemotherapy

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2013, Annals of Surgical Oncology.

Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2015, Clinical lung cancer.

Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients.

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2017, Lung cancer.

A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer

Yi-long Wu, Jin-Ji Yang, Jianxing He, 2020, Investigational New Drugs.

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2013, Lung cancer.

Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status

T. Mok, Yi-long Wu, Jin-Ji Yang, 2012, PloS one.

The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2016, Oncotarget.

Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901).

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2020, Clinical lung cancer.

Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective study.

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2020, Lung cancer.

Retrospective study on bevacizumab in the treatment of non-small cell lung cancer with brain metastases

Yi-long Wu, Jin-Ji Yang, Hong-Hong Yan, 2019, International Journal of Clinical Oncology.

A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002).

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2019, European journal of cancer.

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

Jian Su, Jun Zhao, Qing Zhou, 2018, BMC Cancer.

The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma

Jin-Ji Yang, Yilong Wu, Chongrui Xu, 2016, Oncotarget.

Comparing overall survival between first generation EGFR-TKIs and chemotherapy in lung cancer patients with Del19/L858R

Jin-Ji Yang, Yilong Wu, Y. Lei, 2016, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Integrative Analyses of Lung Squamous Cell Carcinoma in Ten Chinese Patients with Transcriptome Sequencing.

Yi-long Wu, Jin-Ji Yang, Y. Lei, 2015, Journal of genetics and genomics = Yi chuan xue bao.

Prognostic significance of genotype and number of metastatic sites in advanced non-small-cell lung cancer.

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2014, Clinical lung cancer.

A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2014, Lung cancer.

Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2016, Journal of Hematology & Oncology.

EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.

T. Mok, Yi-long Wu, Jin-Ji Yang, 2012, The oncologist.

Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level

Jin-Ji Yang, Yilong Wu, Chongrui Xu, 2019, BMC Cancer.

Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2017, The Lancet. Respiratory medicine.

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

Yi-long Wu, Jin-Ji Yang, Hong-Hong Yan, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.

You Lu, Haiyi Jiang, Kazuhiko Nakagawa, 2015, The Lancet. Oncology.

Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials.

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2014, Lung cancer.

Lung Cancers with Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation

T. Mok, Yi-long Wu, Jin-Ji Yang, 2014, Clinical Cancer Research.

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study.

Jie Yang, T. Mok, Yi-long Wu, 2013, Lung cancer.

Disease Flare After EGFR Tyrosine Kinase Inhibitor Cessation Predicts Poor Survival in Patients with Non-small Cell Lung Cancer

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2013, Pathology & Oncology Research.

Single Nucleotide Polymorphisms in VTI1A Gene Contribute to the Susceptibility of Chinese Population to Non-Small Cell Lung cancer

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2015, The International journal of biological markers.

Rare discrepancies in a driver gene alteration within histologically heterogeneous primary lung cancers.

Jin-Ji Yang, Xue-Ning Yang, W. Zhong, 2015, Lung cancer.

Real-World Scenario of Patients With Lung Cancer Amid the Coronavirus Disease 2019 Pandemic in the People’s Republic of China

Yi-long Wu, Jin-Ji Yang, Chao Zhang, 2020, JTO clinical and research reports.

Clinical features and intervention timing in patients with pregnancy-associated non-small-cell lung cancer

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2021, Journal of thoracic disease.

The predictive value of YAP-1 and POU2F3 for the efficacy of immuno-chemotherapy in extensive-stage SCLC patients.

Yi-long Wu, Jin-Ji Yang, Hui-Ying Liang, 2023, Cancer treatment and research communications.

Stromal PD‐L1–Positive Regulatory T cells and PD‐1–Positive CD8‐Positive T cells Define the Response of Different Subsets of Non–Small Cell Lung Cancer to PD‐1/PD‐L1 Blockade Immunotherapy

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[The Impact of Smoking Status on the Efficacy of Erlotinib in Patients with Advanced Non-small Cell Lung Cancer.].

Jin-Ji Yang, Yilong Wu, Yi-sheng Huang, 2009, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Uncommon ALK fusion partners in advanced ALK-positive non-small-cell lung cancer.

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2018 .

Clinicopathological features and resistance mechanisms in HIP1‐ALK‐rearranged lung cancer: A multicenter study

Jin-Ji Yang, W. Zhong, Pan Wang, 2021, Genes, chromosomes & cancer.

Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.

Yi-long Wu, Jin-Ji Yang, Z. Wang, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer

X. Yi, Jin-Ji Yang, Xue-Ning Yang, 2022, Cancer discovery.

A family history of cancer and lung cancer risk in never-smokers: A clinic-based case-control study.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2015, Lung cancer.

A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel

Ying Cheng, Yi-long Wu, B. Han, 2017, ESMO Open.

BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2013, Molecular Cancer.

Insight into early-phase trials for lung cancer in the United States

Yi-long Wu, Jin-Ji Yang, 2015, Chinese journal of cancer.

P1.01-018 Acquired Resistance to Crizotinib in Advanced NSCLC with De Novo MET Overexpression

Jin-Ji Yang, W. Zhong, Z. Xie, 2017 .

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.

Jie Yang, M. Ahn, T. Mok, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Complete mediastinal lymphadenectomy: the core component of the multidisciplinary therapy in resectable non-small cell lung cancer.

Jin-Ji Yang, Xue-Ning Yang, W. Zhong, 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.

Ying Cheng, Jin-Ji Yang, Jianxing He, 2019, The Lancet. Respiratory medicine.

[Consensus on dignosis for ALK positive non-small cell lung cancer in China, the 2013 version].

Ying Cheng, T. Mok, Yi-long Wu, 2013, Zhonghua bing li xue za zhi = Chinese journal of pathology.

Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2018, Lung cancer.

[Analysis of Differentially Expressed Proteins in Self-Paired Sera of Advanced Non-small Cell Lung Cancer Patients Responsive to Gefinitib.].

Jin-Ji Yang, Xue-Ning Yang, Yilong Wu, 2009, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).

T. Yamanaka, M. Ahn, Yi-long Wu, 2016 .

EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third‐Generation EGFR Tyrosine Kinase Inhibitor Osimertinib

Yi-long Wu, Jin-Ji Yang, Z. Wang, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2019, EBioMedicine.

Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First‐ and Third‐Generation EGFR TKIs and Shifts Allelic Configuration at Resistance

Yi-long Wu, Jin-Ji Yang, Jie Huang, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Lung cancer treatment disparities in China: a question in need of an answer.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2014, The oncologist.

Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial

Ying Cheng, Jin-Ji Yang, Xue-Ning Yang, 2023, Signal Transduction and Targeted Therapy.

P2-221: Adjuvant docetaxel plus carboplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer: preliminary results of the Chinese Society of Lung Cancer randomised controlled trial (CSLC201)

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2007 .

P-645 A randomized trial comparing neoadjuvant gemicitabine plus carboplatin or cisplatin followed by surgery with surgery alone in Clinical Stage IIIA non-small-cell lung cancer (NSCLC)

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2005 .

Expert consensus on treatment for stage III non‐small cell lung cancer

W. Liang, Jin-Ji Yang, Long Chen, 2023, Medicine Advances.

Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor Cells

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2017, Clinical Cancer Research.

Genomic and Transcriptomic Analysis of Neuroendocrine Transformation in ALK-Rearranged Lung Adenocarcinoma After Treatments With Sequential ALK Inhibitors: A Brief Report

Jin-Ji Yang, Chaozheng Zhou, Jie Huang, 2022, JTO Clinical and Research Reports.

Is 18F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2011, Nuclear medicine communications.

Pathological characteristics and tumour immune microenvironment of lung malignancies with RET rearrangement.

Yi-long Wu, Jin-Ji Yang, Jiao Yang, 2023, Cancer treatment and research communications.

Feasibility of computed tomography‐guided core needle biopsy in producing state‐of‐the‐art clinical management in Chinese lung cancer

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2014, Thoracic cancer.

Crizotinib in advanced non-small-cell lung cancer with de novo c-Met overexpression.

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2015 .

Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases.

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2015, Journal of thoracic disease.

High SHP2 expression determines the efficacy of PD‐1/PD‐L1 inhibitors in advanced KRAS mutant non‐small cell lung cancer

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2021, Thoracic Cancer.

Sintilimab versus pembrolizumab in monotherapy or combination with chemotherapy as first-line therapy for advanced non–small cell lung cancer: Results from phase 2, randomized clinical trial (CTONG1901).

Jin-Ji Yang, Xuchao Zhang, Hong-Hong Yan, 2022, Journal of Clinical Oncology.

MA14.05 A Randomized Phase III Trial of Fruquintinib Versus Placebo in Patients with Advanced Non-Small Cell Lung Cancer (FALUCA)

Ying Cheng, C. Bai, Jin-Ji Yang, 2019, Journal of Thoracic Oncology.

Coexistence of MET exon 14 mutations with EGFR mutations in non-small cell lung cancer.

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2017 .

Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer.

Jin-Ji Yang, W. Feng, W. Zhong, 2023, Lung cancer.

SAF-189s in previously treated patients with advanced ALK-rearranged non-small cell lung cancer (NSCLC): Results from the dose-finding portion in a single-arm, first-in-human phase I/II study.

A. Hui, Yi-long Wu, Jin-Ji Yang, 2020 .

Different dissecting orders of the pulmonary bronchus and vessels during right upper lobectomy are associated with surgical feasibility and postoperative recovery for lung cancer patients

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2017, Chinese journal of cancer.

Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2018, Thoracic cancer.

Circulating tumor cells dynamics during chemotherapy predict survival and response in advanced non-small-cell lung cancer patients

Jin-Ji Yang, W. Feng, Xuchao Zhang, 2023, Therapeutic advances in medical oncology.

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2018, BMC Cancer.

Docetaxel as salvage chemotherapy in patients with advanced non-small cell lung cancer after failure of cytotoxic agents and gefitinib treatment

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2008 .

Accidental invisible intrathoracic disseminated pT4-M1a: a distinct lung cancer with favorable prognosis.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2015, Journal of thoracic disease.

Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.

Yi-long Wu, Jin-Ji Yang, Jie Huang, 2021, Clinical lung cancer.

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2016, Oncotarget.

Epidermal growth factor receptor is associated with the onset of skeletal related events in non-small cell lung cancer

Yi-long Wu, Jin-Ji Yang, Shu-Mei Huang, 2017, Oncotarget.

NGS to reveal heterogeneity between cerebrospinal fluid and plasma ctDNA among non-small cell lung cancer patients with leptomeningeal carcinomatosis.

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2017 .

Do-not-resuscitate orders among advanced-stage Chinese lung cancer patients who died in hospital

Yi-long Wu, Jin-Ji Yang, N. Zhao, 2016, Supportive Care in Cancer.

A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study.

Ying Cheng, Jin-Ji Yang, C. Bai, 2020, Lung cancer.

Distribution and prognosis of uncommon metastases from non-small cell lung cancer

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2016, BMC Cancer.

Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2017, Oncotarget.

Response to Icotinib Plus Chemotherapy in Pulmonary Atypical Carcinoid Harboring the EGFR L858R Mutation: A Brief Report

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2021, JTO Clinical and Research Reports.

Principles of biopsy in suspected lung cancer: priority still based on invasion in the era of targeted therapy?

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2013, Journal of thoracic disease.

MA12.08 Chemotherapy plus EGFR TKIs or Bevacizumab versus Chemotherapy Alone in SCLC-Transformed EGFR-Mutant Lung Adenocarcinoma

Junzhou Huang, Jin-Ji Yang, Y. Wu, 2021 .

First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial

Yangqiu Li, Jin-Ji Yang, Chongrui Xu, 2023, Nature Medicine.

A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2014, BMC Cancer.

A Clinical Model to Estimate the Pretest Probability of Lung Cancer, Based on 1198 Pedigrees in China

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase II trial comparing pemetrexed with gefitinib as the second-line treatment of nonsquamous NSCLC patients with wild-type EGFR (CTONG0806).

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2013 .

Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level

Jin-Ji Yang, Yilong Wu, Chongrui Xu, 2019, BMC Cancer.

The spatiotemporal evolution of EGFR C797S mutation in EGFR-mutant non-small cell lung cancer: opportunities for third-generation EGFR inhibitors re-challenge.

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2019, Science bulletin.

Open Access Research

Jianfeng Xu, Jin-Ji Yang, S. Cramer, 2022 .

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial.

W. Mao, Ying Cheng, Jin-Ji Yang, 2020 .

Open Access RESEARCH

Young Yang, Peter Suber, Yi-long Wu, 2010 .